Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

Let's summarize the last few months, scientifically.

There's been a lot of talk lately about warrants and share price and such. However, what matters is how is this company going to boost it's share price and make us money. The answer, is scientific data. That's all that matters. That's what is going to score Algernon the multi-million if not billions in licensing fees or a buy-out.

So, let the science do the talking... and don't forget... they also have a patent on the long forgotten sister drug of ifenprodil, which performed just as well in their animal model. They patented that one too don't forget. I'm not going to re-post the news release, it's freely available on their website. Do your DD.

Ok enough blabbing, here's the science:

1. Pre-clinical research: BioPub interviews are the best thing for those who are new here to watch. They discuss the positive data from animal studies that shows our drugs generated positive signal and treated the disease of interest. One aspect of our drug pipeline is for idiopathic pulmonary fibrosis and chronic cough. Our lead outperforms the best drug big pharma has to offer. Nothing catches BigPharma's attention like a small company that has a more effective drug. Billions of $ of profit are on the line.

Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%

Ifenprodil works for severe acute lung injury and acute respiratory distress syndrome (ARDS) which is what is killing people who get COVID-19, novel coronavirus. Our preclinical testing saved us a lot of time and show that the drug works. Previous studies have shown it's safe. We are going to study it where it is legal, in South Korea.

2. Safety testing usually cost hundreds of millions. We are using repurposed drugs. We have patents protecting Ifenprodil for respiratory diseases (and as I mentioned, another sister drug just as good as Ifenprodil which is being kept quiet...). We are saving the hundreds of millions by using the safe drugs. We are doing some FDA-registered clinical trial testing in the USA. We will show it's safe for injection by IV, as well as oral long acting.

[url][/https://clinicaltrials.gov/ct2/show/NCT04318704url][tag]Registration of Ifenprodil through the American FDA for study - ClinicalTrials.Gov[/tag]

3. Clinical trials: We have NOVOTECH which is a certified CRO which is going to be running our trials. We have funding. We have drug ready to go. We are also producing more drug using a certified American chemistry company. We have NOVOTECH investing there own money in Algernon. FDA and medical regulatory authorities in Australia and South Korea will fast track ifenprofil for COVID-19 related use. Ethics can get approved in days to weeks... the trial can generate positive signal in 2-4 weeks. We have been told the ethics submission and protocol are complete and soon to be submitted. As soon as this trial is ongoing, this will generate global attention. That could be in the next couple of weeks.

4. Why it works:

Coronaviruses may invade the nervous system and we have a drug that protects the neurons.

COVID-19 may invade neurons causing respiratory failure

coronaviruses invade the nervous syste,

It protects them by working on the NMDA receptor.

NMDA receptor

The nervous system invasion by the virus can cause a lot of inflammatory mediators (aka inflammation) to be release and that causes the NMDA receptor to cause neuron injury. This is important because our drug blocks that.

already doctors are publishing work showing covid-19 hurts the nervous system

And like I said before, here's how our drug works:

Coronavirus infection induces increased production of proinflammatory cytokines and neuronal degeneration as a consequence of glutamate excitotoxicity. In physiological conditions, glutamate is mainly synthesized by neurons and released in the synaptic cleft as the primary excitatory neurotransmitter of the CNS that activates the ligand-dependant receptor AMPAr, which allows the entry of sodium ions and the passage of the nerve impulse in the post-synaptic neuron, leading to activation of the NMDA receptor (N-methyl-D-aspartate receptor) that allows the entry of calcium ions. During infection of neurons by coronavirus, microglial cells detect the presence of virus and produce pro-inflammatory cytokines (TNF-alpha, IL-1 beta and IL-6) that down-regulate the astrocytic receptor GLT-1 (glutamate transporter 1) and prevent the efficient recapture of glutamate. This situation disturbs the regulation of glutamate homeostasis and theexcess of this neurotransmitter in the synaptic cleft leads to excitotoxicity associated with a massive entry of calcium which eventually leads to degeneration of and death of neuronal cells.

This is why NMDA ANTAGONIST IFENPRODIL is going to be helpful for saving neurons!

Ifenprodil works on the NMDA receptor on neurons.

NMDA receptor

And SARS-COV-2 aka COVID-19 hurts the neurons:

Neuroinvasive potential of COVID-19 may hurt respiratory drive and cause respiratory failure

This study shows NMDA receptor plays a role in neuronal cell death:

Review of how NMDA involved in neuronal cell death

So Ifenprodil may actually help keep the neurons alive. It might help people from failing to breath.


MAKE SMART INVESTMENTS AND TRUST THE SCIENCE BECUASE IT IS WHAT PAYS